{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:42:58Z","timestamp":1762004578249,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T00:00:00Z","timestamp":1528502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Although the mortality rates of cirrhosis are underestimated, its socioeconomic burden has demonstrated a significant global impact. Cirrhosis is defined by the disruption of normal liver architecture after years of chronic insult by different etiologies. Treatment modalities are recommended primarily in decompensated cirrhosis and specifically tailored to the different manifestations of hepatic decompensation. Antifibrogenic therapies are within an active area of investigation. The endocannabinoid system has been shown to play a role in liver disease, and cirrhosis specifically, with intriguing possible therapeutic benefits. The endocannabinoid system comprises cannabinoid receptors 1 (CB1) and cannabinoid receptor 2 (CB2) and their ligands, endocannabinoids and exocannabinoids. CB1 activation enhances fibrogenesis, whereas CB2 activation counteracts progression to fibrosis. Conversely, deletion of CB1 is associated with an improvement of hepatic fibrosis and steatosis, and deletion of CB2 results in increased collagen deposition, steatosis, and enhanced inflammation. CB1 antagonism has also demonstrated vascular effects in patients with cirrhosis, causing an increase in arterial pressure and vascular resistance as well as a decrease in mesenteric blood flow and portal pressure, thereby preventing ascites. In mice with hepatic encephalopathy, CB1 blockade and activation of CB2 demonstrated improved neurologic score and cognitive function. Endocannabinoids, themselves also have mechanistic roles in cirrhosis. Arachidonoyl ethanolamide (AEA) exhibits antifibrogenic properties by inhibition of HSC proliferation and induction of necrotic death. AEA induces mesenteric vasodilation and hypotension via CB1 induction. 2-arachidonoyl glycerol (2-AG) is a fibrogenic mediator independent of CB receptors, but in higher doses induces apoptosis of HSCs, which may actually show antifibrotic properties. 2-AG has also demonstrated growth-inhibitory and cytotoxic effects. The exocannabinoid, THC, suppresses proliferation of hepatic myofibroblasts and stellate cells and induces apoptosis, which may reveal antifibrotic and hepatoprotective mechanisms. Thus, several components of the endocannabinoid system have therapeutic potential in cirrhosis.<\/jats:p>","DOI":"10.3390\/medicines5020052","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T11:01:01Z","timestamp":1528714861000},"page":"52","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Role of Cannabinoids in the Setting of Cirrhosis"],"prefix":"10.3390","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3979-7200","authenticated-orcid":false,"given":"Pratima","family":"Dibba","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Women and Infants Hospital\/Warren Alpert School of Medicine, Brown University, Providence, RI 02905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, CA 94304, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Cholankeril","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94304, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umair","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mary Imogene Bassett Hospital, Cooperstown, NY 13326, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiranjeevi","family":"Gadiparthi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Tennessee Health Science Center, Memphis, TN 38163, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ali","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Tennessee Health Science Center, Memphis, TN 38163, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1919-6800","authenticated-orcid":false,"given":"Donghee","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94304, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-8586","authenticated-orcid":false,"given":"Aijaz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94304, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,9]]},"reference":[{"key":"ref_1","first-page":"756","article-title":"Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation","volume":"74","author":"Heidelbaugh","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"ref_2","first-page":"661","article-title":"The Current Economic Burden of Cirrhosis","volume":"7","author":"Neff","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/MCG.0000000000000208","article-title":"The epidemiology of cirrhosis in the United States: A population-based study","volume":"49","author":"Scaglione","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Byass, P. (2014). The global burden of liver disease: A challenge for methods and for public health. BMC Med., 12.","DOI":"10.1186\/s12916-014-0159-5"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16820","DOI":"10.3748\/wjg.v20.i45.16820","article-title":"Non-invasive diagnosis of advanced fibrosis and cirrhosis","volume":"20","author":"Sharma","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_6","unstructured":"Centers for Disease Control and Prevention (2018, May 16). Chronic Liver Disease and Cirrhosis, Available online: http:\/\/www.cdc.gov\/nchs\/fastats\/liver-disease.htm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.3748\/wjg.v20.i23.7260","article-title":"Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update","volume":"20","author":"Elpek","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s004410051073","article-title":"The cell biology of liver fibrogenesis\u2014An imbalance of proliferation, growth arrest and apoptosis of myofibroblasts","volume":"292","author":"Gressner","year":"1998","journal-title":"Cell Tissue Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.3748\/wjg.v20.i23.7312","article-title":"Pathogenesis of liver cirrhosis","volume":"20","author":"Zhou","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_10","unstructured":"Friedman, S.L. (2013). Pathogenesis of Hepatic Fibrosis, UpToDate."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Abraldes","year":"2017","journal-title":"Hepatology"},{"key":"ref_13","unstructured":"Thornton, K. (2018, May 18). Lesson 5. Evaluation and Prognosis of Patients with Cirrhosis. Available online: https:\/\/www.hepatitisc.uw.edu\/go\/evaluation-staging-monitoring\/evaluation-prognosis-cirrhosis\/core-concept\/all."},{"key":"ref_14","first-page":"767","article-title":"Cirrhosis and chronic liver failure: Part II. Complications and treatment","volume":"74","author":"Heidelbaugh","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.26359","article-title":"Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012","volume":"57","author":"Runyon","year":"2013","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2010). EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol., 53, 397\u2013417.","DOI":"10.1016\/j.jhep.2010.05.004"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1476-5381.2011.01397.x","article-title":"The endocannabinoid system as a key mediator during liver diseases: New insights and therapeutic openings","volume":"163","author":"Mallat","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/hep.24077","article-title":"Endocannabinoids in liver disease","volume":"53","author":"Tam","year":"2011","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cld.527","article-title":"Cannabinoids in liver diseases","volume":"7","author":"Patsenker","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jhep.2015.01.001","article-title":"Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis","volume":"62","author":"Silvestri","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dc16-0650","article-title":"Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel group pilot study","volume":"39","author":"Jadoon","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"G850","DOI":"10.1152\/ajpgi.00523.2007","article-title":"Endocannabinoids and Liver Disease. III. Endocannabinoid effects on immune cells: Implications for inflammatory liver diseases","volume":"294","author":"Pacher","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nm1421","article-title":"CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis","volume":"12","author":"Julien","year":"2006","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/liv.12263","article-title":"The endocannabinoid system in advanced liver cirrhosis: Pathophysiological implication and future perspectives","volume":"33","author":"Baldassarre","year":"2013","journal-title":"Liver Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2004.12.050","article-title":"Antifibrogenic role of the cannabinoid receptor CB2 in the liver","volume":"128","author":"Julien","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_26","first-page":"58","article-title":"Endocannabinoids as novel mediators of liver diseases","volume":"29","author":"Mallat","year":"2006","journal-title":"J. Endocrinol. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/jpet.107.131896","article-title":"Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats","volume":"324","author":"Ros","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1042\/CS20060260","article-title":"Effect of chronic CB1 cannabinoid receptor antagonism on livers of rats with biliary cirrhosis","volume":"112","author":"Yang","year":"2007","journal-title":"Clin. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1073\/pnas.1017689108","article-title":"Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver","volume":"108","author":"Mukhopadhyay","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.3748\/wjg.14.6109","article-title":"Role of cannabinoids in chronic liver diseases","volume":"14","author":"Parfieniuk","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jhep.2013.03.032","article-title":"Cannabinoid signaling and liver therapeutics","volume":"59","author":"Mallat","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.gastro.2009.01.004","article-title":"Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis","volume":"137","author":"Domenicali","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1478-3231.2005.01180.x","article-title":"Endocannabinoids and liver disease\u2014Review","volume":"25","author":"Gabbay","year":"2005","journal-title":"Liver Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1053\/j.gastro.2007.11.039","article-title":"Daily cannabis use: A novel risk factor of steatosis severity in patients with chronic hepatitis C","volume":"134","author":"Zafrani","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2017.03.008","article-title":"Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B","volume":"59","author":"Dai","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1478-3231.2011.02496.x","article-title":"Role of cannabinoid receptors in alcoholic hepatic injury: Steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts","volume":"31","author":"Trebicka","year":"2011","journal-title":"Liver Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1476-5381.2010.00756.x","article-title":"The plant cannabinoid \u03949-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice","volume":"160","author":"Bolognini","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","unstructured":"Bose, J., Hedden, S.L., Lipari, R.N., Park-Lee, E., Porter, J.D., and Pemberton, M.R. (2018, May 20). Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health, Available online: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-FFR1-2015\/NSDUH-FFR1-2015\/NSDUH-FFR1- 2015."}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/5\/2\/52\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:07:58Z","timestamp":1760195278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/5\/2\/52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,9]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["medicines5020052"],"URL":"https:\/\/doi.org\/10.3390\/medicines5020052","relation":{},"ISSN":["2305-6320"],"issn-type":[{"type":"electronic","value":"2305-6320"}],"subject":[],"published":{"date-parts":[[2018,6,9]]}}}